• 1
    Marie I, Ducrotte P, Denis P, et al. Oesophageal mucosal involvement in patients with systemic sclerosis receiving proton pump inhibitor therapy. Aliment Pharmacol Ther 2006; 24: 1593601.
  • 2
    Hurwitz AL, Duranceau A, Postlethwait RW. Esophageal dysfunction and Raynaud’s phenomenon in patients with scleroderma. Dig Dis 1976; 21: 6016.
  • 3
    Wipff J, Allanore AN, Soussi F, et al. Prevalence of Barrett’s esophagus in systemic sclerosis. Arthritis Rheum 2005; 52: 28828.
  • 4
    Derk CT, Rasheed M, Artlett CM, et al. A cohort study of cancer incidence in systemic sclerosis. J Rheumatol 2006; 33: 11136.
  • 5
    Segel MC, Campbell WL, Medsger TA Jr, et al. Systemic sclerosis (scleroderma) and esophageal adenocarcinoma: is increased patient screening necessary? Gastroenterology 1985; 89: 4858.